Delayed resolution of vitreomacular traction syndrome following intravitreal injection of ocriplasmin

Detalhes bibliográficos
Autor(a) principal: Moreira, Jorge
Data de Publicação: 2017
Outros Autores: Teixeira, Carla, Gonçalves, Rita, Coelho, Pedro, Maio, Tiago
Tipo de documento: Relatório
Idioma: eng
Título da fonte: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Texto Completo: https://doi.org/10.48560/rspo.11824
Resumo: Introduction: Ocriplasmin is the first pharmacological treatment option approved for the treatment of vitreomacular traction (VMT), including those associated with macular holes. Resolution of vitreomacular adhesion is typically observed within 28 days of intravitreal ocriplasmin injection with the vast majority of patients experiencing vitreomacular release within the first 7 days of treatment. Methods: We report two cases of symptomatic VMT, in which we observed delayed VMT release after intravitreal ocriplasmin. Results: One month after treatment, there was only partial release of VMT in both cases. Complete VMT resolution was achieved in 4 and 2 months, respectively, following intravitreal ocriplasmin injection. Conclusions: Our case reports shows that favorable results can be observed long after the 28 days established to achieve the final outcome of ocriplasmin treatment, and this may have been facilitated by the initial release of VMT by ocriplasmin. The description of the present case reports adds to the literature suggesting that longer observation may be needed after intravitreal ocriplasmin.
id RCAP_39cd88863f8dfde6506abfe607f92bfd
oai_identifier_str oai:ojs.revistas.rcaap.pt:article/11824
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Delayed resolution of vitreomacular traction syndrome following intravitreal injection of ocriplasminComunicações Curtas e Imagens em OftalmologiaIntroduction: Ocriplasmin is the first pharmacological treatment option approved for the treatment of vitreomacular traction (VMT), including those associated with macular holes. Resolution of vitreomacular adhesion is typically observed within 28 days of intravitreal ocriplasmin injection with the vast majority of patients experiencing vitreomacular release within the first 7 days of treatment. Methods: We report two cases of symptomatic VMT, in which we observed delayed VMT release after intravitreal ocriplasmin. Results: One month after treatment, there was only partial release of VMT in both cases. Complete VMT resolution was achieved in 4 and 2 months, respectively, following intravitreal ocriplasmin injection. Conclusions: Our case reports shows that favorable results can be observed long after the 28 days established to achieve the final outcome of ocriplasmin treatment, and this may have been facilitated by the initial release of VMT by ocriplasmin. The description of the present case reports adds to the literature suggesting that longer observation may be needed after intravitreal ocriplasmin.Ajnet2017-10-31T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/reporthttps://doi.org/10.48560/rspo.11824eng1646-69501646-6950Moreira, JorgeTeixeira, CarlaGonçalves, RitaCoelho, PedroMaio, Tiagoinfo:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2022-09-22T17:06:03Zoai:ojs.revistas.rcaap.pt:article/11824Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T10:22:11.241411Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Delayed resolution of vitreomacular traction syndrome following intravitreal injection of ocriplasmin
title Delayed resolution of vitreomacular traction syndrome following intravitreal injection of ocriplasmin
spellingShingle Delayed resolution of vitreomacular traction syndrome following intravitreal injection of ocriplasmin
Moreira, Jorge
Comunicações Curtas e Imagens em Oftalmologia
title_short Delayed resolution of vitreomacular traction syndrome following intravitreal injection of ocriplasmin
title_full Delayed resolution of vitreomacular traction syndrome following intravitreal injection of ocriplasmin
title_fullStr Delayed resolution of vitreomacular traction syndrome following intravitreal injection of ocriplasmin
title_full_unstemmed Delayed resolution of vitreomacular traction syndrome following intravitreal injection of ocriplasmin
title_sort Delayed resolution of vitreomacular traction syndrome following intravitreal injection of ocriplasmin
author Moreira, Jorge
author_facet Moreira, Jorge
Teixeira, Carla
Gonçalves, Rita
Coelho, Pedro
Maio, Tiago
author_role author
author2 Teixeira, Carla
Gonçalves, Rita
Coelho, Pedro
Maio, Tiago
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Moreira, Jorge
Teixeira, Carla
Gonçalves, Rita
Coelho, Pedro
Maio, Tiago
dc.subject.por.fl_str_mv Comunicações Curtas e Imagens em Oftalmologia
topic Comunicações Curtas e Imagens em Oftalmologia
description Introduction: Ocriplasmin is the first pharmacological treatment option approved for the treatment of vitreomacular traction (VMT), including those associated with macular holes. Resolution of vitreomacular adhesion is typically observed within 28 days of intravitreal ocriplasmin injection with the vast majority of patients experiencing vitreomacular release within the first 7 days of treatment. Methods: We report two cases of symptomatic VMT, in which we observed delayed VMT release after intravitreal ocriplasmin. Results: One month after treatment, there was only partial release of VMT in both cases. Complete VMT resolution was achieved in 4 and 2 months, respectively, following intravitreal ocriplasmin injection. Conclusions: Our case reports shows that favorable results can be observed long after the 28 days established to achieve the final outcome of ocriplasmin treatment, and this may have been facilitated by the initial release of VMT by ocriplasmin. The description of the present case reports adds to the literature suggesting that longer observation may be needed after intravitreal ocriplasmin.
publishDate 2017
dc.date.none.fl_str_mv 2017-10-31T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/report
format report
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.48560/rspo.11824
url https://doi.org/10.48560/rspo.11824
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1646-6950
1646-6950
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Ajnet
publisher.none.fl_str_mv Ajnet
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833590765698154496